Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: Initial experience in patients with acute peripheral arterial occlusions

American Journal of Roentgenology

Volumn 178, Issue 3, 2002, Pages 617-622

  Yoon, Hyo Chun ^a   Miller Jr , Franklin J ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036182066     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.178.3.1780617     Document Type: Article

References (24)

1. Human platelets possess an inducible and saturable receptor specific for fibrinogen
2. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets
3. Aurin tricarboxylic acid: A novel inhibitor of the association of von Willebrand factor and platelets
4. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets
5. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators: Platelet glycoprotein IIb/IIIa in unstable angina - Receptor suppression using Intergrilin therapy
7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms - (PRISM-PLUS) study investigators
8. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II - Eptifibatide to minimise platelet aggregation and coronary thrombosis-II
9. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: The EPILOG investigators
10. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: The RESTORE investigators - Randomized efficacy study of tirofiban for outcomes and restenosis
11. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis
12. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: The STILE trial
13. Thrombolysis in the management of lower limb peripheral arterial occlusion: A consensus document
14. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
15. Disposition of 14C-eptifibatide after intravenous administration to healthy men
16. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
17. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature - The advisory panel
18. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion
19. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: A randomized trial
20. Thrombolytic therapy with recombinant human tissue-type plasminogen activator: A comparison of two doses
21. Peripheral arterial occlusions: Local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA)
22. Thrombolysis with tissue-plasminogen-activator: Results with a high-dose transthrombus technique
23. The use of recombinant human tissue-type plasminogen activator (rt-PA) in both grafts and native arteries in the lower limb: Results over a 2-year period
24. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: Results and complications